Posted by Michael Wonder on 16 Dec 2016
CymaBay Therapeutics announces that MBX-8025 has received European Medicines Agency PRIority MEdicines (PRIME) designation for the treatment of primary biliary cholangitis
20 October 2016 - CymaBay Therapeutics today announced that MBX-8025 has been granted the PRIority MEdicine (PRIME) designation by the EMA for the treatment of primary biliary cholangitis in patients who do not tolerate or respond to ursodeoxycholic acid (UDCA) or do not respond to combination UDCA/obeticholic acid treatment.
MBX-8025 is an orally administered potent and selective peroxisome proliferator-activated receptor delta agonist currently in Phase 2 clinical development.
